Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Measles is one of the 10 most important causes of death due to infectious diseases
- Peter Panum's observations
- Paramyxoviridae: Morbilliviruses
- Mononegavirales Paramyxoviridae Morbillivirus: Measles virus
- MeV attachment: 3 cellular receptors for H identified
- Measles virus replication
- Measles virus cytopathic effect: Syncytia
- Transmission is by aerosol or respiratory droplets
- R0 (infectiousness) for some important human viruses
- Pathogenesis of measles: Virus replication
- Measles P mRNA also encodes two non-structural proteins
- Pathogenesis of measles: Clinical disease
- Measles rash
- Pathogenesis of measles: Virus clearance
- Clearance of MeV and MeV RNA from PBMCs and lymph nodes
- Measles virus-infected cells during acute viremia
- Measles complications per 100,000 cases
- Measles: Causes of death
- Early descriptions of immune suppression during measles
- Pathogenesis of measles: protective immunity
- Life-long immunity
- Pathogenesis conclusions
- Derivation of live attenuated measles virus vaccines in 1950s
- Vaccine licensing in 1963
- Measles eradication
- Measles case distribution by month and WHO region (2015–2019)
- Measles incidence rate per million (12M period)
- Distribution of measles genotypes (2018–2019)
- Current measles vaccine
- Immunization coverage with first dose of measles containing vaccines in infants, 2014
- Population immunity – 1 dose
- Achieving 2 dose coverage
- Measles is occurring primarily in unvaccinated persons: e.g. Switzerland
- Failure of measles control
- Summary
- Conclusions
Topics Covered
- Introduction to measles as a systemic rash disease
- Measles virus and replication
- Virus proteins for cell entry, fusion and formation of multinucleated giant cells
- Transmission, systemic spread, immune response, complications and clearance
- Vaccine characteristics, efficacy and coverage
- Measles epidemiology
- Problems with control
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Griffin, D.E. (2020, April 29). Measles [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 7, 2024, from https://doi.org/10.69645/PYYR1662.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose.
A selection of talks on Immunology
Transcript
Please wait while the transcript is being prepared...
0:00
This is Diane Griffin, Professor of Johns Hopkins Bloomberg School of Public Health,
and we're going to be talking about measles.
0:09
So measles is typically a childhood rash disease.
Despite the fact that we have an excellent vaccine about which we'll talk more later,
it remains one of the 10 most important causes of death due to infectious disease.
0:24
So the earliest understanding of the epidemiology of measles which
has been very important and carries through to our current understanding of measles,
although we understand much more about the basis for this epidemiology now,
occurred due to the work of Peter Panum,
who was a Danish physician who was sent to the Faroe Islands in 1846.
This is well before we knew measles was caused by a virus,
it was well before we knew measles was even an infectious disease.
The last time that the Faroe Islands,
which are quite away from the continent of Europe but are a protectorate of Denmark,
had had a measles outbreak was 60 years before.
What Peter Panum observed was that the disease was contagious,
that you didn't get measles unless you'd been exposed to somebody who had it,
that it had a 14-day incubation period between
the time of exposure and the onset of the rash disease,
and importantly observed that all the people
who lived on the island at the time of the previous outbreaks,
60 years before, were protected from
disease and essentially everybody else got the disease.
So it was very infectious.
But if you had it, you develop lifelong immunity to reinfection.
1:36
So the virus that we now know causes measles belongs to
the family of paramyxoviridae and morbilliviruses.
There's a group of morbilliviruses,
some of which you may be familiar with,
particularly canine distemper virus.
Dogs usually get vaccine against canine distemper,
but these viruses are fairly species specific.
So many species have their own morbillivirus,
and the human morbillivirus is measles virus.
It also infects non-human primates,
although they're not an important reservoir,
and it's most closely related to rinderpest virus.
Rinderpest is a disease of cattle,
very serious disease of cattle,
and it's likely that measles virus arose
from rinderpest to become adapted to become a human virus.
Another interesting feature of rinderpest is that it was actually
eradicated fairly recently in the last few years through vaccination.
So that raised the hope that we might be able to do the same thing for measles virus,
and one of the things we'll discuss is why we're having trouble accomplishing that.